Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Systemic Therapy for Melanoma: ASCO Guideline.

Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P.

J Clin Oncol. 2020 Mar 31:JCO2000198. doi: 10.1200/JCO.20.00198. [Epub ahead of print]

PMID:
32228358
2.

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy.

Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M.

Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36364-X. doi: 10.1016/j.annonc.2020.03.285. [Epub ahead of print] Review.

PMID:
32194150
3.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A.

J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012.

PMID:
32135517
4.

Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.

Gandhi S, Pandey M, Ammannagari N, Wang C, Bucsek MJ, Hamad L, Repasky E, Ernstoff MS.

Immunotherapy. 2020 Feb;12(2):141-149. doi: 10.2217/imt-2019-0064. Epub 2020 Feb 17.

PMID:
32064978
5.

Purity and yield of melanoma exosomes are dependent on isolation method.

Shu S, Yang Y, Allen CL, Hurley E, Tung KH, Minderman H, Wu Y, Ernstoff MS.

J Extracell Vesicles. 2019 Nov 20;9(1):1692401. doi: 10.1080/20013078.2019.1692401. eCollection 2020.

6.

Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.

Abdou Y, Kapoor A, Hamad L, Ernstoff MS.

Medicine (Baltimore). 2019 Nov;98(44):e17769. doi: 10.1097/MD.0000000000017769.

7.

Oncologist uptake of comprehensive genomic profile guided targeted therapy.

Nesline MK, DePietro P, Dy GK, Early A, Papanicolau-Sengos A, Conroy JM, Lenzo FL, Glenn ST, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Puzanov I, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Frederick P, Lele S, Gardner M, Morrison C.

Oncotarget. 2019 Jul 23;10(45):4616-4629. doi: 10.18632/oncotarget.27047. eCollection 2019 Jul 23.

8.

Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.

Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta HM, Miller HE, Olson M, Rajasekaran K, Ernstoff MS, Wang D, Malarkannan S, Wang L.

Cancer Immunol Res. 2019 Sep;7(9):1497-1510. doi: 10.1158/2326-6066.CIR-18-0489. Epub 2019 Jul 24.

9.

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.

Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang CJ, Yarchoan R, Cheever MA; Cancer Immunotherapy Trials Network (CITN)-12 Study Team.

JAMA Oncol. 2019 Jun 2. doi: 10.1001/jamaoncol.2019.2244. [Epub ahead of print]

PMID:
31154457
10.

Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for Melanoma.

LeBlanc RE, Barton DT, Li Z, Angeles CV, Ernstoff MS, Bagley E, Wimmer D, Wong SL, Barth RJ Jr, Shirai K, Yan S.

Am J Surg Pathol. 2019 Jun;43(6):755-765. doi: 10.1097/PAS.0000000000001229.

PMID:
31091203
11.

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.

Agrawal N, Khunger A, Vachhani P, Colvin TA, Hattoum A, Spangenthal E, Curtis AB, Dy GK, Ernstoff MS, Puzanov I.

Case Rep Oncol. 2019 Mar 21;12(1):260-276. doi: 10.1159/000498985. eCollection 2019 Jan-Apr.

12.

A Review of Exosomes and their Role in The Tumor Microenvironment and Host-Tumor "Macroenvironment".

Tung KH, Ernstoff MS, Allen C, Shu S.

J Immunol Sci. 2019;3(1):4-8. doi: 10.29245/2578-3009/2019/1.1165. Epub 2019 Jan 10.

13.

Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment.

Shu S, Yang Y, Allen CL, Maguire O, Minderman H, Sen A, Ciesielski MJ, Collins KA, Bush PJ, Singh P, Wang X, Morgan M, Qu J, Bankert RB, Whiteside TL, Wu Y, Ernstoff MS.

Sci Rep. 2019 Mar 15;9(1):4959. doi: 10.1038/s41598-018-37179-1.

14.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

15.

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

PMID:
30865922
16.

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.

Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C.

BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. doi: 10.1186/s12911-019-0743-x.

17.

Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gérard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst BA, Saenger YM.

Clin Cancer Res. 2019 Apr 15;25(8):2494-2502. doi: 10.1158/1078-0432.CCR-18-2847. Epub 2019 Jan 15.

PMID:
30647081
18.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

19.

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM.

Cancer. 2018 Nov 15;124(22):4332-4341. doi: 10.1002/cncr.31734. Epub 2018 Oct 10.

20.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
21.

Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.

Overman MJ, Ernstoff MS, Morse MA.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:239-247. doi: 10.1200/EDBK_200821. Review.

22.

Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment.

Shu S, Yang Y, Allen CL, Maguire O, Minderman H, Sen A, Ciesielski MJ, Collins KA, Bush PJ, Singh P, Wang X, Morgan M, Qu J, Bankert RB, Whiteside TL, Wu Y, Ernstoff MS.

Sci Rep. 2018 Aug 27;8(1):12905. doi: 10.1038/s41598-018-31323-7. Erratum in: Sci Rep. 2019 Mar 15;9(1):4959.

23.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

24.

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.

Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L, Lutzky J, Luna TL, Aung S, Lawson DH.

J Immunother Cancer. 2018 Jul 27;6(1):76. doi: 10.1186/s40425-018-0387-x.

25.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

26.

Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.

Gorlov I, Orlow I, Ringelberg C, Hernando E, Ernstoff MS, Cheng C, Her S, Parker JS, Thompson CL, Gerstenblith MR, Berwick M, Amos C.

Melanoma Res. 2018 Oct;28(5):380-389. doi: 10.1097/CMR.0000000000000473.

27.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

28.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

29.

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.

Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, Angeles CV, Turk MJ, Ernstoff MS.

Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121. doi: 10.1007/s00262-018-2169-1. Epub 2018 May 8.

PMID:
29737375
30.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
31.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

32.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

33.

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors.

Conroy JM, Pabla S, Glenn ST, Burgher B, Nesline M, Papanicolau-Sengos A, Andreas J, Giamo V, Lenzo FL, Hyland FCL, Omilian A, Bshara W, Qin M, He J, Puzanov I, Ernstoff MS, Gardner M, Galluzzi L, Morrison C.

J Mol Diagn. 2018 Jan;20(1):95-109. doi: 10.1016/j.jmoldx.2017.10.001. Epub 2017 Oct 20.

34.

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.

Montano R, Khan N, Hou H, Seigne J, Ernstoff MS, Lewis LD, Eastman A.

Oncotarget. 2017 Jun 28;8(40):67754-67768. doi: 10.18632/oncotarget.18834. eCollection 2017 Sep 15.

35.

Challenges faced when identifying patients for combination immunotherapy.

Ernstoff MS, Gandhi S, Pandey M, Puzanov I, Grivas P, Montero A, Velcheti V, Turk MJ, Diaz-Montero CM, Lewis LD, Morrison C.

Future Oncol. 2017 Aug;13(18):1607-1618. doi: 10.2217/fon-2017-0218. Epub 2017 Aug 24. Review.

PMID:
28835114
36.

NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.

Godbersen C, Coupet TA, Huehls AM, Zhang T, Battles MB, Fisher JL, Ernstoff MS, Sentman CL.

Mol Cancer Ther. 2017 Jul;16(7):1335-1346. doi: 10.1158/1535-7163.MCT-16-0846. Epub 2017 May 12.

37.

Emerging role of RNA binding protein UNR/CSDE1 in melanoma.

Gandhi S, Ito F, Ernstoff MS.

J Xiangya Med. 2017 May;2. pii: 41. doi: 10.21037/jxym.2017.03.12. Epub 2017 May 5. No abstract available.

38.

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.

Thomas AA, Fisher JL, Hampton TH, Christensen BC, Tsongalis GJ, Rahme GJ, Whipple CA, Steel SE, Davis MC, Gaur AB, Lewis LD, Ernstoff MS, Fadul CE.

Cancer Immunol Immunother. 2017 Mar;66(3):379-389. doi: 10.1007/s00262-016-1941-3. Epub 2016 Dec 9.

PMID:
27942839
39.

Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.

Yan S, Holderness BM, Li Z, Seidel GD, Gui J, Fisher JL, Ernstoff MS.

Anticancer Res. 2016 Dec;36(12):6449-6456.

40.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

41.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

42.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.

Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.

43.

Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient.

Gastman BR, Ernstoff MS.

Ann Oncol. 2016 Dec;27(12):2304-2305. doi: 10.1093/annonc/mdw293. Epub 2016 Aug 8. No abstract available.

44.

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.

Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS.

Melanoma Res. 2016 Jun;26(3):223-35. doi: 10.1097/CMR.0000000000000244.

PMID:
26974965
45.

Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients.

Ko JS, Prieto VG, Elson PJ, Vilain RE, Pulitzer MP, Scolyer RA, Reynolds JP, Piliang MP, Ernstoff MS, Gastman BR, Billings SD.

Mod Pathol. 2016 Feb;29(2):122-30. doi: 10.1038/modpathol.2015.109. Epub 2015 Nov 6.

47.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.

N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

48.

Development and validation of a melanoma risk score based on pooled data from 16 case-control studies.

Davies JR, Chang YM, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green A, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Lee TK, Le Marchand L, Mackie RM, Olsson H, Østerlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus L, Zens MS, Ziegler A, Gallagher RP, Barrett JH, Newton-Bishop J.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):817-24. doi: 10.1158/1055-9965.EPI-14-1062. Epub 2015 Feb 24.

49.

Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.

Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, Olek S, Schwachula T, Rhodes CH, Gui J, Tafe LJ, Tsongalis GJ, Lefferts JA, Wishart H, Kleen J, Miller M, Whipple CA, de Abreu FB, Ernstoff MS, Fadul CE.

Neuro Oncol. 2015 Jun;17(6):801-9. doi: 10.1093/neuonc/nou363. Epub 2015 Jan 24.

50.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

Supplemental Content

Loading ...
Support Center